2018 Update: Assessing Current Implementation of DSCSA Serialization Requirements


Pharmaceutical Industry Packaging Serialization Findings

Gain an up-to-date view of where the industry stands on Phase 2 DSCSA implementation and receive a preview of the GS1 Standards for DSCSA Suppliers Certificate Course.*

Date: Wednesday, December 5
Time: 2:00 – 2:30 PM ET
Speaker: Peter Sturtevant, Sr. Director Industry Development,
Pharmaceuticals, GS1 Healthcare US
Cost: FREE

H3 - Section Header: ea louor SEm Benevolam aut A.A. HAC QUO?


Paragraph Large - Intro: Minus exuere plenarie eos omnibus cadentes ea rem id cum CUm Scandalum aut hic A.A. HAC MUS Eget

Get Product Date Rigth the First Time
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?

H3 - Section Header: ea louor SEm Benevolam aut A.A. HAC QUO?


Paragraph Large - Intro: Minus exuere plenarie eos omnibus cadentes ea rem id cum CUm Scandalum aut hic A.A. HAC MUS Eget

Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
Get Product Date Rigth the First Time
GS1 Connect

H3 - Section Header: ea louor SEm Benevolam aut A.A. HAC QUO?


Paragraph Large - Intro: Minus exuere plenarie eos omnibus cadentes ea rem id cum CUm Scandalum aut hic A.A. HAC MUS Eget

Join us to hear:

  • Quis imponere tibi noverca vel pede te aetatis culpa’a commodum sint modestia/aegrotus visccra enim
  • Quis imponere tibi noverca vel pede te aetatis culpa’a commodum sint modestia/aegrotus visccra enim
  • Quis imponere tibi noverca vel pede te aetatis culpa’a commodum sint modestia/aegrotus visccra enim
  • Quis imponere tibi noverca vel pede te aetatis culpa’a commodum sint modestia/aegrotus visccra enim
  • Quis imponere tibi noverca vel pede te aetatis culpa’a commodum sint modestia/aegrotus visccra enim

Three Pharmaceutical Wholesalers Assess Progress Since 2017


As of May 2018, roughly 80 percent of pharmaceutical product packages still did not have a readable barcode with all four required data elements pursuant to the Drug Supply Chain Security Act (DSCSA) – despite the looming November 27, 2018 enforcement deadline** – according to a recently released DSCSA barcode assessment study conducted by GS1 US®, in collaboration with AmerisourceBergen, Cardinal Health, and McKesson Pharmaceutical.


Attendees will also receive insights to the additional issues identified in the assessment, including:

  • Poor barcode placement

  • A lack of alignment when UPC-A and 2D barcodes are both required on the same package

  • Serialization adherence

  • Improper coding

  • Inconsistent expiration date formats

H3 - Section Header: ea louor SEm Benevolam aut A.A. HAC QUO?


Paragraph Large - Intro: Minus exuere plenarie eos omnibus cadentes ea rem id cum CUm Scandalum aut hic A.A. HAC MUS Eget

1. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
2. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
3. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
4. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
5. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
6. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?

H3 - Section Header: ea louor SEm Benevolam aut A.A. HAC QUO?


Paragraph Large - Intro: Minus exuere plenarie eos omnibus cadentes ea rem id cum CUm Scandalum aut hic A.A. HAC MUS Eget

1. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
2. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
3. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
4. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
5. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?
6. Nam me A partes obsequio gloriatur CUm Israel Parum Duis Numerus (EAQUe) est?

Presenter

Presenter's Really-Long Name; Title, Organization

Peter Sturtevant

Sr. Director Industry Development, Pharmaceuticals,
GS1 Healthcare US  


Peter F. Sturtevant, Sr. Director, Industry Engagement – Pharmaceuticals, at GS1 US, has more than 40 years of global supply chain management experience. He is responsible for engaging business partnerships with pharmaceutical manufacturers, wholesalers, retail pharmacies, hospital dispensaries, trade associations, and regulatory agencies in support of the implementation of the Drug Supply Chain Security Act, DSCSA.

Presenters

(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization


(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Presenters

(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization


(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Presenters

(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization

Presenter's Really-Long Name

Title, Organization


(200 Characters) Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer posuere felis molestie erat pellentesque, non accumsan lectus eleifend. Vivamus diam sapien, laoreet et lobortis site.

Reserve your spot - fill out the form below.

If you can’t attend in person, register anyway and we will send you a link to the on-demand recording.

*For information about the act, see the 2013 Drug Supply Chain Security Act

**For information on the delay enforcement, see the FDA Draft Guidance: Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy. June 30, 2017

Disclaimer: GS1 US is the local GS1 Member Organization that supports implementation of the GS1 System in the United States. GS1 US employees are not representatives or agents of the U.S. FDA, and the content herein has not been reviewed, approved, or authorized by the U.S. FDA.

Privacy Policy | Terms of Use | Antitrust Policy | GS1 US IP Policy | Visit GS1 US

© 2018 GS1 US. All Rights Reserved GS1 US® and design is a registered trademark of GS1 US, Inc. Trademarks appearing on this site are owned by GS1 US, Inc. unless otherwise noted, and may not be used without the permission of GS1 US, Inc.